Annual revenue fell from KRW 60.7 billion in 2022 to KRW 46.4 billion in 2023, a 23.5% decline, then rose 15.9% to KRW 53.8 billion in 2024 and 24.9% to KRW 67.2 billion in 2025, marking two consecutive years of growth.
Behind the 2023 low, one brokerage analysis points to European sales resuming only after May 2023, and the company classified its lithotripter and blood glucose businesses as discontinued operations in the second half of 2023.
Operating profit was KRW 20.3 billion in 2022, KRW 14.1 billion in 2023 (down 30.8%), KRW 17.6 billion in 2024 (up 25.0%) and KRW 20.7 billion in 2025 (up 17.6%). Operating margin ran at 33.5% in 2022, 30.3% in 2023, 32.7% in 2024 and 30.8% in 2025, staying in the low-to-mid 30s percent range.
The 2025 margin was lower than in 2024, but faster revenue growth lifted absolute operating profit. Net income attributable to controlling shareholders was KRW 19.1 billion in 2022, KRW 12.8 billion in 2023 (down 33.2%), KRW 18.3 billion in 2024 (up 42.9%) and KRW 20.3 billion in 2025 (up 11.2%).
For 2022 through 2024, net income including non-controlling interests was disclosed at KRW 19.1 billion, KRW 12.8 billion and KRW 18.3 billion, the same amounts as attributable net income. On February 25, 2026, the company said revenue and operating profit both set all-time highs since its 1991 founding in 2025.
By quarter, Q3 2025 revenue was KRW 17.1 billion, operating profit KRW 5.75 billion and attributable net income KRW 4.94 billion, followed by Q1 2026 revenue of KRW 16.7 billion, operating profit of KRW 4.91 billion and attributable net income of KRW 4.83 billion.
Q2 2026 revenue rose to KRW 19.8 billion, up 18.1% from the prior quarter, with operating profit of KRW 5.8 billion and attributable net income of KRW 5.83 billion.
Q3 2026 revenue was KRW 18.4 billion, down 6.7% from the prior quarter but up 8.0% year on year, while operating profit was KRW 5.02 billion, down 13.4% quarter on quarter and 12.6% year on year.
The same quarter swung attributable net income to a loss of KRW 5.75 billion, while operating profit stayed positive, so the reason the two lines diverged is the next point to check. Net income attributable to controlling shareholders over the last four quarters totaled KRW 10 billion.
Operating cash flow fell from KRW 8.59 billion in 2022 and KRW 17.8 billion in 2023 to KRW 23.7 billion in 2024 and KRW 14.9 billion in 2025. The debt ratio rose from 6.4% in 2023 to 12.6% in 2025, with total liabilities of KRW 15.9 billion at end-2025.